Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and
safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of
digestive carcinoma.